key: cord-0703663-8ksnihp6
authors: Smith, Kristen M.; Yacobi, Rinat; Van Etten, Richard A.
title: Autoinhibition of Bcr-Abl through Its SH3 Domain
date: 2003-07-29
journal: Mol Cell
DOI: 10.1016/s1097-2765(03)00274-0
sha: d8a35f92d6cd93110fa20d42442f96b111b86f42
doc_id: 703663
cord_uid: 8ksnihp6

Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regulated through its SH3 domain. Kinase activity, transformation, and leukemogenesis by Bcr-Abl are greatly impaired by mutations of the Bcr coiled-coil domain that disrupt oligomerization, but restored by an SH3 point mutation that blocks ligand binding or a complementary mutation at the intramolecular SH3 binding site defined in c-Abl. Phosphorylation of tyrosines in the activation loop of the catalytic domain and the linker between the SH2 and catalytic domains (SH2-CD linker) is dependent on oligomerization and required for leukemogenesis. These results suggest that Bcr-Abl has a monomeric, unphosphorylated state with the SH3 domain engaged intramolecularly to Pro1124 in the SH2-CD linker, the form that is sensitive to the inhibitor imatinib (STI-571). The sole function of the coiled-coil domain is to disrupt the autoinhibited conformation through oligomerization and intermolecular autophosphorylation.

The functional domains of the p210 Bcr-Abl protein are depicted, including (from left to right) Bcr exons 1-13 including the coiled-coil (CC) oligomerization domain and Abl exons 2-11 including the SH3 domain with location of Pro1013, the SH2 domain, the SH2-CD linker region with Pro1124 and Tyr1127, kinase domain with location of activation loop Tyr1294, three nuclear localization signals, DNA and actin binding domains, nuclear export signal, and the location of the BstEII site in the cDNA. Abl fusion proteins found in Ph ϩ leukemia patients (p190, per domain of murine coronavirus spike protein abolish oligomerization and biological activity (Luo et al., 1999) . p210, and p230). To investigate the role of the Bcr coiledcoil domain in regulating catalytic activity, cellular transformation, and leukemogenesis by p210 Bcr-Abl, we Bcr-Abl Coiled-Coil Domain Mutations Impair Oligomerization In Vivo generated a series of mutations that are predicted to disrupt the coiled-coil domain while leaving the extreme Bcr-Abl is predicted to form oligomers through the coiled-coil domain. To assess oligomerization by the N terminus of Bcr-Abl intact. p210⌬cc removes amino acids 31 to 69 and deletes the entire coiled-coil domain coiled-coil domain mutants, we generated additional constructs that were truncated at a C-terminal BstEII ( Figure 1C ). p210F54P mutates phenylalanine at position 54 to proline ( Figure 1G) and is similar to a proline-con-site: p210⌬cc/⌬BX, p210F54P/⌬BX, and p210LZA/⌬BX ( Figures 1D, 1H, and 1M ). The full-length and truncated taining peptide insertion mutant described previously . The F54P mutation places a constructs were coexpressed in 293T cells and immunoprecipitated with the GEX5 antibody (C) that recognizes proline in the middle of the domain and is predicted to disrupt the coiled-coil by introducing a kink to the middle only the full-length protein (Figure 2A, lane 3) . The antibody pEX2 (N) recognizes and immunoprecipitates both of the ␣ helix. The third mutant, p210LZA ( Figure 1L ), has point mutations at the "a" and "d" positions across full-length and truncated p210 proteins (Figure 2A , lane 2). Strong coassociation of the truncated p210 protein the coiled-coil domain, with Val28, Ile31, Leu35, Ile42, Leu45, Val49, Met56, Leu59, and Leu63 changed to ala-was seen with full-length p210 (Figure 2A) whereas the truncated p210⌬cc no longer associated with the full-nine. These point mutations are predicted to conserve the helical structure of the coiled-coil but replace the length version. Likewise, coassociation of the full-length and truncated p210 proteins was lost in the presence residues essential for stabilization of the dimer structure. Similar alanine substitution mutations in the leucine zip-of either the F54P or LZA mutations. Thus, in vivo oligo- to stimulate Abl kinase activity (Brasher and Van Etten, 2000) . Surprisingly, the in vivo catalytic activity of p210 was relatively unaffected by the F54P mutation. This merization of p210 Bcr-Abl is dependent on an intact appeared to be the consequence of residual oligomeramphipathic coiled-coil domain.

ization of this mutant protein, because substitution of alanines for the "a" and "d" coiled-coil residues of p210F54P resulted in very low kinase activity (Figure 3 , Decreased In Vivo Tyrosine Kinase Activity of Bcr-Abl Coiled-Coil Deletion and Alanine Substitution compare p210F54P and p210F45P/LZA). These results demonstrate that oligomerization is required for dysreg-Mutants Is Restored by Loss of SH3 Function We next assessed the in vivo tyrosine kinase activity of ulation of Bcr-Abl kinase activity in vivo. Previous studies demonstrated that transformation of the Bcr-Abl coiled-coil mutant proteins. We transduced interleukin-3 (IL-3)-dependent Ba/F3 hematopoietic cytokine-dependent hematopoietic cell lines by Bcr-Abl lacking amino acids 1-63 can be partially rescued by cells with BCR-ABL retroviruses, selected G418-resistant populations in the presence of IL-3, and prepared deletion of the SH3 domain (Maru et al., 1996) . To determine whether the in vivo tyrosine kinase activity of oligo-extracts after IL-3 deprivation. The Bcr-Abl coiled-coil mutant proteins were consistently expressed at levels merization-defective Bcr-Abl can be restored by loss of SH3 ligand binding function, we generated two addi-higher than wild-type p210 Bcr-Abl (Figure 3 , bottom panel), suggesting that oligomerization of Bcr-Abl may tional sets of Bcr-Abl mutants. In the first set, proline 1013 was mutated to leucine to generate p210⌬cc/ affect the stability of the protein in vivo, possibly because activated Abl proteins are more sensitive to pro-P1013L, p210F54P/P1013L, and p210LZA/P1013L (Figures 1E, 1I, and 1N ). This mutation, which corresponds teasomal degradation (Echarri and Pendergast, 2001 Addition of either the P1013L or P1124L mutations to p210⌬cc or p210LZA increased levels of cellular phosphotyrosine to that of wild-type p210-expressing cells without grossly altering the spectrum of phosphorylated proteins (Figure 3 ), but had little effect on the high constitutive activity of p210F54P. These data demonstrate that loss of SH3 ligand binding function restores maximal in vivo catalytic activity to Bcr-Abl in the absence of oligomerization.

To determine the impact of oligomerization on Bcr-Abl transforming activity, we tested the ability of the coiledcoil mutants to induce the anchorage-independent growth of fibroblasts. NIH The LZA mutation also significantly reduced transformation of NIH 3T3 fibroblasts. The p210F54P mutant transformed fibroblasts nearly as efficiently as wild-type p210, but mutation of the hydrophobic leucine zipper residues to alanine (p210F54P/LZA; see Figure 1K ) abolished transformation, again suggesting that the F54P 

Bcr-Abl Coiled-Coil Deletion and Alanine Substitution effect on the robust transforming activity of p210F54P.

Mutants Are Defective for Transformation of Primary Thus, point mutations in the Abl SH3 domain or its puta-Bone Marrow B-Lymphoid Progenitors tive intramolecular ligand can compensate for inactivat-To assess transformation of primary bone marrow ing mutations in the coiled-coil domain. B-lymphoid progenitors by the Bcr-Abl coiled-coil mu-To confirm that the SH3 point mutations do not affect tants, freshly harvested bone marrow was transduced oligomerization of the p210 coiled-coil mutants, we generwith BCR-ABL retroviruses. When plated under Whitlockated additional constructs that were truncated at the Witte conditions, p210 Bcr-Abl stimulates the outgrowth N-terminal BstEII site, p210⌬cc/P1013L/⌬BX, p210F54P/ of immature B-lymphoid cells that are stroma dependent P1013L/⌬BX, and p210LZA/P1013L/⌬BX. The full-length and not highly leukemogenic in mice (McLaughlin et al., and truncated constructs were coexpressed in 293T 1987). We have modified this assay to include serial cells and immunoprecipitated as described above. None dilution and plating of the transduced bone marrow, of the coiled-coil/P1013L double mutant proteins coaswhich allows for a qualitative assessment of transformasociated in vivo ( Figure 2B ), arguing that rescue of fibrotion ( Figure 5 ). p210 Bcr-Abl expression resulted in the blast transformation activity by SH3 mutation is not due rapid outgrowth of cultures initiated with as few as 3 ϫ to restoration of Bcr-Abl oligomerization. 10 3 cells under these conditions ( Figure 5A ), while only The c-Abl kinase is activated fully following sequential adherent stromal cells were seen in cultures of untransautophosphorylation at two sites: Tyr412 in the activaduced cells ( Figure 5B ). The coiled-coil deletion or alation loop of the catalytic domain and Tyr245 in the linker nine substitution mutants were completely defective in region between the SH2 and catalytic domains (Brasher this assay, with no detectable growth even at the highest and Van Etten, 2000). Using tyrosine to phenylalanine plating density (Figures 5C and 5F ). Expression of substitution mutants, we examined the requirement for p210F54P resulted in growth of some wells at higher these sites for Bcr-Abl kinase activity and transformaplating densities, but growth of the lower dilutions was tion. Mutation of either the homologous activation loop impaired relative to wild-type p210 ( Figure 5I ), while the tyrosine (Tyr1294) or the SH2-CD linker tyrosine (Tyr1127) p210F54P/LZA double mutant was completely inactive alone modestly decreased Bcr-Abl in vivo kinase activ-( Figure 5O ). Transformation by all three coiled-coil doity, while a Y1127/1294F double mutant displayed even main mutants was significantly increased by secondary lower activity (Figure 3 ). Tyr to Phe mutation at either mutations in the SH3 or SH2-CD linker sites, particularly position was sufficient to abolish fibroblast transformaby the P1124L mutation, which restored transformation tion by Bcr-Abl ( Figure 4A ). Taken together, these results to the level of wild-type p210 in all cases. Expression of demonstrate that loss of either oligomerization or auto-p210Y1294F resulted in modestly decreased cell growth phosphorylation results in defective fibroblast transforrelative to that induced by wild-type p210 ( Figure 5M ), mation by Bcr-Abl.

while the Y1127F and Y1127/1294F mutants showed no growth at any cell plating density ( Figures 5L and 5N ). These results demonstrate that oligomerization and au-Bcr-Abl Coiled-Coil Deletion and Alanine Substitution tophosphorylation are required for transformation of pri-

Transformation of fibroblasts and hematopoietic cell lines by Bcr-Abl mutants does not correlate well with for growth in the absence of IL-3 ( Figure 4B ). Like p210 Bcr-Abl, the p210F54P construct was able to support their ability to induce leukemia in vivo (Van Etten, 2002), emphasizing the need to assess the role of Bcr-Abl rapid IL-3-independent growth. In contrast, p210⌬cc and p210LZA induced greatly diminished proliferation oligomerization, SH3 function, and autophosphorylation in leukemogenesis. Hence, we tested the ability of the under the same conditions. If followed for an additional 48 hr, cultures expressing p210⌬cc or p210LZA reached Bcr-Abl coiled-coil mutants to induce CML-like myeloproliferative disease in mice using the bone marrow ret-confluence (data not shown), demonstrating that oligomerization of Bcr-Abl enhances IL-3-independent growth roviral transduction/transplantation model. In this assay, mice transplanted with p210-transduced bone marrow but is not absolutely required for transformation of these cells, in agreement with more recent work ( Figure 6) , characterized by peripheral blood leukocytosis with greatly increased neutro-p210LZA resulted in IL-3 independent growth that was comparable to that of cells expressing wild-type p210 phils, hepatosplenomegaly, and infiltration of spleen, liver, and lungs with maturing myeloid cells (Li et al., 1999) . (Figures 4C and 4D) . As in fibroblasts, the loss of Bcr-

Balb/c bone marrow was transduced with the indicated BCR-ABL retrovirus and plated at indicated cell numbers per well in triplicate wells. Nontransduced cells were added to 10 6 total cells to provide stromal support. Wells were scored as positive when the viable nonadherent cell number reached 10 6 /well. Although p210Y1294F was previously reported to be defective in this assay (Pendergast et al., 1993) , this might be due to low virus titer in that study.

In contrast, mice transplanted with marrow transduced antsev et al., 2001). These results demonstrate that efficient oligomerization through the coiled-coil domain and with p210⌬cc or p210LZA failed to develop CML-like disease, but instead succumbed to T-lymphoid leuke-maximal levels of Bcr-Abl kinase activity are required for induction of CML. mia/lymphoma (T-ALL) after a long latent period ( Figures  6A and 6B) 

The P1013L SH3 mutation rescued efficient induction of CML-like disease by p210⌬cc ( Figure 6A) 

implicates directly the ligand binding function of the SH3 thymus, and a hemorrhagic malignant pleural effusion that was the cause of death ( Figure 6C) . The same dis-domain in the rescue mechanism. The P1124L SH2-CD linker mutation also restored induction of CML-like ease is induced by p210 Bcr-Abl with a point mutation in the SH2 domain that impairs catalytic activity (Roumi-disease by p210⌬cc although less efficiently ( Figure 6A ). Likewise, mutation at either Pro1013 or Pro1124 re-had myeloproliferative disease with splenomegaly and peripheral blood leukocytosis, but eventually succumbed stored induction of CML-like myeloproliferative disease by p210LZA ( Figure 6B) 

Mutation of the homolog of the major autophosphory-tion ( Figure 5G ). The P1124L mutation rescued p210LZA more effectively, with five of seven recipients developing lation site in c-Abl significantly attenuated leukemogenesis by p210 Bcr-Abl, with the majority of recipients of CML-like disease and the remaining two animals developing T-ALL and histiocytic sarcoma (HS), another Bcr-p210Y1294F-transduced marrow developing CML-like disease but only after a significant delay ( Figure 6D ).

Single mutation of the homolog of the c-Abl secondary autophosphorylation site in the SH2-CD linker (Y1127F) 1999). Interestingly, the P1013L mutation also partially rescued induction of myeloproliferative disease by had no effect on leukemogenesis, but p210 lacking both potential autophosphorylation sites (p210Y1127/1294F) p210F54P, with three of eight recipients developing typical CML-like disease and one succumbing to simultane-was severely impaired for induction of CML-like disease, with the majority of mice lacking evidence of myeloprolif-ous CML and B-ALL. The remaining mice in this cohort erative disease and developing T-lymphoma ( Figure 6D) .

and Van Etten, 1997). Thus, further studies are necessary before we will have a complete understanding of c-Abl The precise mechanism of dysregulation of c-Abl tyroregulation. sine kinase activity upon fusion of Bcr sequences to the Given these new insights into c-Abl regulation, how Abl N terminus has been unclear despite intensive study.

is 

like myeloproliferative disease in mice. The low but deduces rapid phosphorylation at Tyr245, which may distectable in vivo tyrosine kinase of monomeric Bcr-Abl place the SH3 domain from the adjacent Pro242 site, may reflect loss of a portion of the Abl N-terminal cap and results in a highly active enzyme with activity equivand the myristoyl group. The p210F54P mutant exhibalent to SH3-mutated c-Abl. Physiological activation of ited significant in vivo kinase and cell transforming activc-Abl may involve auto-or trans-phosphorylation of ity that likely reflects residual oligomerization unde-Tyr412, perhaps by a Src family kinase (Plattner et al., tected by our stringent coimmunoprecipitation assay, 1999), followed by loss of self-inhibition by the SH3 because the p210F54P/LZA double mutant had low kidomain.

nase activity and was completely defective for transfor-Although the SH3 domains of Abl and Src carry out mation. Phosphorylation of Bcr-Abl at two key regulasimilar autoinhibitory functions, the two kinases differ tory tyrosines is both dependent on oligomerization and in one important regulatory feature. A C-terminal phosrequired for leukemogenesis, demonstrating that the photyrosine in Src family kinases (Tyr527 in c-Src) funccritical event induced by Bcr-Abl oligomerization is likely tions as an intramolecular SH2 domain binding site to be intermolecular autophosphorylation.

Complete deletion of the SH3 domain can restore cell of kinase activity. c-Abl is unphosphorylated in its inactransformation by Bcr-Abl lacking the coiled-coil dotive state (Van Etten et al., 1995) and, lacking this SH2main (Maru et al., 1996) , but the mechanism involved C-terminal interaction, employs other mechanisms to was also unknown. We demonstrated that in vivo kinase stabilize its inactive conformation. In the case of type activity, cellular transformation, and leukemogenesis by Ib c-Abl, recent studies demonstrate that sequences the Bcr-Abl coiled-coil deletion and alanine substitution N-terminal to the SH3 domain (the N-terminal "cap") mutants were restored by a point mutation (P1013L) in bind to the Abl catalytic domain (Pluk et al., 2002) Bcr-Abl has an autoregulated state that is similar to c-Abl, and our results provide direct proof of this hypoth-

Structural mechanism for STI-571 inhibition of kinase activity in vitro permits direct comparison of normal and altered abl gene products

Cell signaling by receptor tyrosine kinases

Multiple BCR-ABL kinase domain 1399-1412. mutations confer polyclonal resistance to the tyrosine kinase imatinib (STI571) in chronic phase and blast crisis chronic myeloid leu

tutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to Sicheri

Activation of c-Abl kinase SH3 domain reactivates de-oligomerized BCR-ABL for growth factor activity and transformation by a chemical inducer of dimerization. independence

Studying the pathogenesis of BCR-ABL ϩ mation of immature hematopoietic cells by the P210 bcr/abl oncoleukemia in mice

gene product of the Philadelphia chromosome

Introduction of a loss-of-function point mutation from the SH3 region

An actin-binding function of the Caenorhabditis elegans sem-5 gene activates the transcontributes to transformation by the Bcr-Abl oncoprotein of the forming ability of c-abl in vivo and abolishes binding of proline-rich Philadelphia chromosome-positive leukemias

The PAG gene product

Effect of Bcr sequences stress-induced protein with antioxidant properties, is an Abl SH3-on the cellular function of the Bcr-Abl oncoprotein. Oncogene 15, binding protein and a physiological inhibitor of c-Abl tyrosine kinase 1625-1634. activity

The NH 2 -terminal coiled-coil domain and tyrosine 177 play coil oligomerization domain of Bcr is essential for the transforming important roles in induction of a myeloproliferative disease in mice function of Bcr-Abl oncoproteins

Structure of the Bcr-Abl oncoprotein oligomerization domain. mice by the Bcr/Abl tyrosine kinase

Structural basis for the autoinhibition of c-Abl tyrosine kinase

The Abl family kinases: mechanisms of regulation and signaling

Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF

A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1

Autoinhibition of c-Abl

The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

Clinical resistance to the kinase inhibitor STI-571 in CML by mutation of Tyr253 in the Abl kinase domain P-loop